AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31392048 — intervention group
Group type: COMPARATOR
Intervention: Long-acting octreotide
Number of subjects: 91
Study 31392200 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver depot gene therapy using an AAV vector for GAA production
Number of subjects: 0
Study 31392200 — intervention group
Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (GAA)
Number of subjects: 0
Study 31392500 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait parameters measured in patients with axSpA
Number of subjects: 60
Study 31392500 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls
Number of subjects: 60
Study 31392710 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling (SHC)
Number of subjects: 78
Study 31392710 — intervention group
Group type: COMPARATOR
Intervention: Whole body cooling (WBC)
Number of subjects: 78
Study 31393220 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity function assessment in patients with multiple sclerosis
Number of subjects: 0
Study 31393220 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder position sense assessment in patients with multiple sclerosis
Number of subjects: 0
Study 31393220 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability level assessment in patients with multiple sclerosis
Number of subjects: 0
Study 31393222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing reported in family (Afghanistan)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing reported in family (oPT)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing because of hunger (Afghan married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with easier access to money in emergency (Afghan married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with intimate partner violence (Afghan married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with IPV and mother-in-law violence (Afghan married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with easier access to money in emergency (Afghan unmarried women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with household violence (Afghan unmarried women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with more childhood traumas (Afghan unmarried women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with more patriarchal personal gender attitudes (Afghan unmarried women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with experiencing IPV (oPT married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing and experiencing IPV (oPT married women)
Number of subjects: 1996
Study 31393873 — intervention group
Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing because of hunger (oPT unmarried women)
Number of subjects: 1996
Study 31394007 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT) after conditioning with cyclophosphamide and rituximab.
Number of subjects: 617
Study 31394007 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 617
Study 31394574 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III)
Number of subjects: 80
Study 31394594 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory/vestibular evaluations (rotational chair, videonystagmography, computerized dynamic posturography, vestibular evoked myogenic potentials, retinal fundoscopy)
Number of subjects: 75
Study 31394594 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory/vestibular evaluations
Number of subjects: 75
Study 31394596 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants with measurable hearing loss
Number of subjects: 69
Study 31394596 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants with no measurable hearing loss
Number of subjects: 69
Study 31394596 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants with no measurable hearing loss but reported hearing concerns
Number of subjects: 69
Study 31394596 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults without brain injury)
Number of subjects: 69
Study 31394598 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants
Number of subjects: 71
Study 31394598 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants with high anxiety or post-traumatic stress
Number of subjects: 71
Study 31394598 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants with high anxiety, post-traumatic stress or depression
Number of subjects: 71
Study 31394598 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of mTBI group with abnormal tandem gait and high anxiety
Number of subjects: 71
Study 31394598 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 71
Study 31394598 — intervention group
Group type: COMPARATOR
Intervention: Normative controls
Number of subjects: 71
Study 31394828 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Adipokines, Growth Factors, and Cytokines
Number of subjects: 50
Study 31394994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) only
Number of subjects: 1135
Study 31394994 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT followed by EVT
Number of subjects: 1135
Study 31395011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Burst Suppression periods
Number of subjects: 97
Study 31395019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care coordination (TCC) and patient navigation intervention
Number of subjects: 84
Study 31395089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks.
Number of subjects: 3655
Study 31395089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab at 200 mg every 3 weeks after complete resection in patients with stage III melanoma.
Number of subjects: 3655
Study 31395100 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (Pembrolizumab + Axitinib, AGEN1884, Pembrolizumab)
Number of subjects: 7
Study 31395100 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (specific mention of AGEN1884)
Number of subjects: 7
Study 31395100 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (Pembrolizumab, switched to Nivolumab/Ipilimumab)
Number of subjects: 7
Study 31395100 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (general)
Number of subjects: 7
Study 31395124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting with syncope to the ED
Number of subjects: 1397
Study 31395124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients hospitalized (47% of total)
Number of subjects: 1397
Study 31395124 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (2 years)
Number of subjects: 1397
Study 31395124 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (2 years) in hospitalized patients
Number of subjects: 1397
Study 31395436 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver PTX stents
Number of subjects: 13
Study 31395600 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant (AlloSCT)
Number of subjects: 500
Study 31395600 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (AuSCT)
Number of subjects: 500
Study 31395600 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloSCT
Number of subjects: 500
Study 31395600 — intervention group
Group type: EXPERIMENTAL
Intervention: AuSCT
Number of subjects: 500
Study 31395751 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily) and Buparlisib (80 mg once daily)
Number of subjects: 89
Study 31395751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Binimetinib and Buparlisib)
Number of subjects: 89
Study 31396142 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids- and Omega 3-Based Compound
Number of subjects: 0
Study 31396142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31396983 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168 200 μg (single abdominal subcutaneous injection)
Number of subjects: 23
Study 31397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Directly Observed Therapy (Mobile DOT)
Number of subjects: 34
Study 31397845 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (Tresiba)
Number of subjects: 1167
Study 31398081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV) and Brentuximab Vedotin (1.8 mg/kg IV) every 3 weeks
Number of subjects: 30
Study 31398082 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775 (150 mg/d) in combination with gemcitabine (1,000 mg/m²) and radiation
Number of subjects: 34
Study 31398204 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based deworming intervention, specific dosage and duration not mentioned
Number of subjects: 0
Study 31398204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deworming intervention)
Number of subjects: 0
Study 31398245 — intervention group
Group type: COMPARATOR
Intervention: Ovarian cortex tissue obtained from 10 TS patients after unilateral ovariectomy; analysis of X chromosomal content of oocytes and granulosa cells.
Number of subjects: 10
Study 31398245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cortex stromal cells from TS patients; analysis of X chromosomal content.
Number of subjects: 10
Study 31398245 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of extra-ovarian cells (lymphocytes, buccal cells, urine cells) from the same patients.
Number of subjects: 10
Study 31398307 — intervention group
Group type: EXPERIMENTAL
Intervention: Segesterone acetate/ethinyl estradiol contraceptive vaginal system (SA/EE CVS)
Number of subjects: 2070
Study 31399043 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1 based oncolytic immunotherapy with GALV-GP-R
Number of subjects: 29
Study 31399043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with PD1/L1-targeted immune checkpoint blockade
Number of subjects: 29
Study 31399109 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated mesenchymal stem cells (S-MSCs) cultured in endothelial growth medium
Number of subjects: 0
Study 31399109 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 31399255 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg daily)
Number of subjects: 48
Study 31399439 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills, Confidence, and Preparedness Index (SCPI) used in diabetes self-management education (DSME) program
Number of subjects: 405
Study 31399936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg QD for 8-21 days)
Number of subjects: 3
Study 31399936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (21-day-on, 7-day-off schedule after surgery)
Number of subjects: 3
Study 31399936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (monotherapy)
Number of subjects: 3
Study 31400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard of care of automated text-messaging and monitoring (AMM) and repeat HIV/STI testing assessment procedures (n=690)
Number of subjects: 1500
Study 31400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group peer support via private social media plus AMM (n=270)
Number of subjects: 1500
Study 31400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching that is strengths-based, youth-centered, unscripted, based on common practice elements of EBI, available over 24 months, and delivered by near-peer paraprofessionals via text, phone, and in-person, plus AMM (n=270)
Number of subjects: 1500
Study 31400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group peer support plus coaching and AMM (n=270)
Number of subjects: 1500
Study 31400325 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative systematic inflammation-immune score (SIS)
Number of subjects: 660
Study 31400383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephrin A2-targeted liposomal prodrug at an equitoxic dose of 50 mg taxane/kg
Number of subjects: 0
Study 31400383 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel at a dose of 10 mg/kg
Number of subjects: 0
Study 31400502 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Number of subjects: 0
Study 31400502 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine Kinase Inhibitors
Number of subjects: 0
Study 31400961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with idarubicin and cytarabine
Number of subjects: 44
Study 31400961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 44
Study 31401102 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 222
Study 31401102 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-anthracycline N-terminal prohormone of brain natriuretic peptide
Number of subjects: 222
Study 31401102 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LVEF and LVEF change post-anthracycline
Number of subjects: 222
Study 31401588 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicorp module (3-day pre-HO intervention)
Number of subjects: 208
Study 31401607 — intervention group
Group type: COMPARATOR
Intervention: tDCS (sham, 0.5 mA, 1 mA, 1 mA, 2 mA) applied over the dorsolateral prefrontal cortex for up to three, 20 min sessions.
Number of subjects: 10
Study 31401903 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31401975 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural-network analysis using four CK metabolic parameters
Number of subjects: 178
Study 31402238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) - 3 doses
Number of subjects: 37
Study 31402382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sero-low group (10 volunteers)
Number of subjects: 19
Study 31402382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sero-high group (9 volunteers)
Number of subjects: 19
Study 31402382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sero-high group
Number of subjects: 19
Study 31402867 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine; dosage and duration not specified
Number of subjects: 0
Study 31402867 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study 31403338 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31403970 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected AF persistent >24 h
Number of subjects: 243
Study 31403970 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected AF
Number of subjects: 243
Study 31403970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortex-involved lesions
Number of subjects: 243
Study 31404542 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg twice per day for 7 days)
Number of subjects: 68
Study 31404569 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 1747
Study 31404569 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 1747
Study 31404569 — intervention group
Group type: EXPERIMENTAL
Intervention: Any framing message
Number of subjects: 1747
Study 31404569 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP recommendation
Number of subjects: 1747
Study 31404569 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 1747
Study 31404569 — intervention group
Group type: COMPARATOR
Intervention: Vaccine-offered condition
Number of subjects: 1747
Study 31404802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg open-label for 8 weeks
Number of subjects: 21
Study 31404802 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21
Study 31404882 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Function (EF) training
Number of subjects: 709
Study 31404882 — intervention group
Group type: COMPARATOR
Intervention: Poor Executive Function (EF)
Number of subjects: 709
Study 31405666 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 18
Study 31405822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rogaratinib at 800 mg twice daily
Number of subjects: 126
Study 31405950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 13
Study 31406470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the MyPlate meal pattern
Number of subjects: 843
Study 31406470 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fizzy drinks and fast food ≥1 time/week
Number of subjects: 843
Study 31406470 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fresh fruit
Number of subjects: 843
Study 31406564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccines with autologous tumor antigens
Number of subjects: 72
Study 31406569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid optimisation and blood pressure control using a non-invasive system
Number of subjects: 0
Study 31406569 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 31406690 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 128
Study 31406985 — intervention group
Group type: EXPERIMENTAL
Intervention: Parechovirus A infections
Number of subjects: 158
Study 31407002 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-drug combinations (specific combinations include amoxicillin/clavulanate and diclofenac with steroid hormones)
Number of subjects: 48
Study 31407002 — intervention group
Group type: COMPARATOR
Intervention: Single drugs
Number of subjects: 48
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets and growth factors (GFs)
Number of subjects: 26
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets
Number of subjects: 26
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: P-selectin
Number of subjects: 26
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble VCAM-1 and ICAM-3
Number of subjects: 26
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher VCAM-1 and ICAM-3 and lower P-selectin
Number of subjects: 26
Study 31407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating markers of vascular injury
Number of subjects: 26
Study 31407236 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 38
Study 31407236 — intervention group
Group type: COMPARATOR
Intervention: glimepiride
Number of subjects: 38
Study 31407321 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine
Number of subjects: 13064
Study 31407321 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine
Number of subjects: 13064
Study 31407321 — intervention group
Group type: COMPARATOR
Intervention: Not in a romantic relationship
Number of subjects: 13064
Study 31407321 — intervention group
Group type: COMPARATOR
Intervention: In a relationship but not living together
Number of subjects: 13064
Study 31408415 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 or more MET hours per week of physical activity
Number of subjects: 1218
Study 31408415 — intervention group
Group type: COMPARATOR
Intervention: Less than 3 MET hours per week of physical activity
Number of subjects: 1218
Study 31408438 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 3
Study 31408438 — intervention group
Group type: COMPARATOR
Intervention: mTOR signaling
Number of subjects: 3
Study 31408668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Breast Irradiation
Number of subjects: 0
Study 31408668 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31409287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (prophylaxis) in the OTTILIA registry
Number of subjects: 0
Study 31409287 — intervention group
Group type: COMPARATOR
Intervention: Not specified (control group in FIRST registry)
Number of subjects: 0
Study 31409297 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) as home-based support for PMTCT services
Number of subjects: 70
Study 31409398 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E immunization
Number of subjects: 195
Study 31409407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) sessions: 60 sessions of 90 minutes at 100% oxygen at 2 ATA with 5 min air breaks every 20 min, 5 days per week.
Number of subjects: 88
Study 31409544 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioural therapy (Tele-CBT)
Number of subjects: 43
Study 31409575 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC (talimogene laherparepvec)
Number of subjects: 60
Study 31410175 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation ablation (IRE) therapy
Number of subjects: 3
Study 31410294 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes intervention (4-week health literacy training, disease knowledge education, 2 home visits, monthly phone counseling for 24 weeks)
Number of subjects: 30
Study 31410294 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes intervention
Number of subjects: 30